• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of ccforumBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleCritical CareJournal Front Page
Crit Care. 2007; 11(2): R39.
Published online Mar 21, 2007. doi:  10.1186/cc5726
PMCID: PMC2206459

Effects of epinephrine and vasopressin on end-tidal carbon dioxide tension and mean arterial blood pressure in out-of-hospital cardiopulmonary resuscitation: an observational study

Abstract

Introduction

Clinical data considering vasopressin as an equivalent option to epinephrine in cardiopulmonary resuscitation (CPR) are limited. The aim of this prehospital study was to assess whether the use of vasopressin during CPR contributes to higher end-tidal carbon dioxide and mean arterial blood pressure (MAP) levels and thus improves the survival rate and neurological outcome.

Methods

Two treatment groups of resuscitated patients in cardiac arrest were compared: in the epinephrine group, patients received 1 mg of epinephrine intravenously every three minutes only; in the vasopressin/epinephrine group, patients received 40 units of arginine vasopressin intravenously only or followed by 1 mg of epinephrine every three minutes during CPR. Values of end-tidal carbon dioxide and MAP were recorded, and data were collected according to the Utstein style.

Results

Five hundred and ninety-eight patients were included with no significant demographic or clinical differences between compared groups. Final end-tidal carbon dioxide values and average values of MAP in patients with restoration of pulse were significantly higher in the vasopressin/epinephrine group (p < 0.01). Initial (odds ratio [OR]: 18.65), average (OR: 2.86), and final (OR: 2.26) end-tidal carbon dioxide values as well as MAP at admission to the hospital (OR: 1.79) were associated with survival at 24 hours. Initial (OR: 1.61), average (OR: 1.47), and final (OR: 2.67) end-tidal carbon dioxide values as well as MAP (OR: 1.39) were associated with improved hospital discharge. In the vasopressin group, significantly more pulse restorations and a better rate of survival at 24 hours were observed (p < 0.05). Subgroup analysis of patients with initial asystole revealed a higher hospital discharge rate when vasopressin was used (p = 0.04). Neurological outcome in discharged patients was better in the vasopressin group (p = 0.04).

Conclusion

End-tidal carbon dioxide and MAP are strong prognostic factors for the outcome of out-of-hospital cardiac arrest. Resuscitated patients treated with vasopressin alone or followed by epinephrine have higher average and final end-tidal carbon dioxide values as well as a higher MAP on admission to the hospital than patients treated with epinephrine only. This combination vasopressor therapy improves restoration of spontaneous circulation, short-term survival, and neurological outcome. In the subgroup of patients with initial asystole, it improves the hospital discharge rate.

Introduction

Epinephrine (adrenaline) has been employed for cardiac resuscitation for more than a century, despite the knowledge that it can cause beta-mimetic complications [1-3]. Vasopressin is a potent vasopressor that could become a useful therapeutic alternative in the treatment of cardiac arrest because it has very little effect on pulmonary circulation and ventilation/perfusion mismatch [4-6]. Our previous study shows that vasopressin could become a better alternative to epinephrine [6]. Recent studies have shown that vasopressin is especially beneficial when combined with epinephrine during cardiopulmonary resuscitation (CPR) [1,7].

Several studies show a strong correlation between end-tidal carbon dioxide tension (petCO2) and cardiac output, coronary perfusion pressure (CPP) and cerebral perfusion pressure, restoration of spontaneous circulation (ROSC), and hospital discharge [8-13]. In addition, clinical studies were performed to demonstrate the correlation between mean arterial blood pressure (MAP) and survival as well as the neurological outcome after CPR [14,15].

The aim of this prehospital study was to compare the values of petCO2 and MAP in patients who suffered a cardiac arrest. They were divided in two groups; one was treated with epinephrine and the other with vasopressin. Our goal was to demonstrate that the use of vasopressin during CPR contributes to higher petCO2 and MAP values and thus may have a beneficial impact on survival rate as well as on neurological outcome.

Materials and methods

In this observational prospective study in the town of Maribor, Slovenia (approximately 200,000 inhabitants), we collected data from January 2000 to April 2006 with the approval of the ethical review board of the Ministry of Health. All emergency calls in this period which were classified as out-of-hospital cardiac arrest (OHCA) in adults older than 18 years and which were dispatched to the prehospital emergency unit were included. In the Centre for Emergency Medicine Maribor, we have two prehospital emergency teams, which are advanced life support (ALS) units of three members with adequately equipped road vehicles (an emergency physician and two registered nurses or medical technicians). ALS was provided using a regional protocol that incorporates the standards and guidelines of the European Resuscitation Council (Antwerp, Belgium).

Exclusion criteria of the study were documented terminal illness, successful defibrillation without administration of a vasopressor, and severe hypothermia (< 30°C). We compared petCO2 and MAP in two treatment groups of resuscitated OHCA patients. In the epinephrine group, patients received 1 mg of epinephrine intravenously every three minutes. In the vasopressin/epinephrine group, patients received 40 units of arginine vasopressin (Pitressin; Goldshield Pharmaceuticals Ltd, Surrey, UK) intravenously only or followed by 1 mg of epinephrine every three minutes during CPR. Patient allocation into these two groups depended on the year of incident (vasopressin has been the first therapy in ventricular fibrillation since November 2003 and in asystole since January 2005) and on accessibility of vasopressin in our prehospital unit (intermittently available since November 2000 and regularly available since November 2003). After successful resuscitation, patients were transferred to the intensive care unit of the Teaching Hospital Maribor.

Data were collected and analyzed according to the Utstein criteria. Demographic information, medical data, and petCO2 values were recorded for each patient by the emergency physician.

During resuscitation, the petCO2 values were measured and recorded every minute beginning with the initial postintubation petCO2 (first petCO2 value obtained) and ending with the final petCO2 value at admission to the hospital. The initial MAP was the first measurement of MAP after ROSC, and the final MAP was recorded at admission to the hospital. Measurements of petCO2, arterial blood pressure, and other parameters were performed with a LIFEPACK 12 defibrillator monitor (Physio-Control, Inc., part of Medtronic, Inc., Minneapolis, MN, USA). Hospital records were used for outcome analysis, including assessment of cerebral performance category (CPC), for patients discharged alive.

Data were expressed as mean ± standard deviation or as number (percentage). For analysis of variables, we used the Fisher exact test and the Wilcoxon rank sum test. The Bonferroni correction was applied for multiple comparisons. The null hypothesis was considered to be rejected at p values of less than 0.05. Analyses of independent predictors for ROSC and survival from univariate analysis were performed using a multivariate logistic regression. For statistical analysis, we used SPSS software (version 12.01; SPSS Inc., Chicago, IL, USA).

Results

Out of 636 patients, 38 were excluded from the study because they were successfully defibrillated without administration of a vasopressor. Patients from the recent vasopressin study [6] (patients with initial ventricular fibrillation) were included in this study. There were no significant differences between demographic and initial clinical characteristics in the compared groups: first monitored rhythm, location of arrest, witnessed arrest, etiology of arrest, gender, age, time to initiation of CPR, and initial petCO2 (Tables (Tables11 to to33).

Table 1
Utstein reporting for cardiopulmonary resuscitation in epinephrine and vasopressin groups
Table 3
End-tidal pressure of carbon dioxide and mean arterial blood pressure in two groups of cardiac arrest patients
Table 2
Demographic and clinical characteristics of out-of-hospital cardiac arrest patients

The initial, average, and final values of petCO2 were significantly higher in patients with ROSC on admission to the hospital compared with patients without ROSC in both groups (p < 0.01). All patients with ROSC had an initial petCO2 value greater than 1.33 kPa. The average petCO2 values in patients with and without ROSC and the final petCO2 values in patients with ROSC were significantly higher in the vasopressin/epinephrine group (p < 0.01). The average values of initial and final MAP were significantly higher in the vasopressin/epinephrine group (p < 0.01) (Table (Table33).

In multivariate analysis, initial, average, and final petCO2 values, initial MAP, and use of vasopressin were associated with ROSC and admission to the hospital (Table (Table4);4); initial, average, and final petCO2 values, final MAP, and use of vasopressin were associated with survival at 24 hours (Table (Table5);5); initial, average, and final petCO2 values and final MAP were associated with final survival and hospital discharge (Table (Table6).6). Vasopressin/epinephrine therapy was not associated with improved hospital discharge.

Table 4
Variables associated with restoration of spontaneous circulation and hospital admission
Table 5
Variables associated with survival at 24 hours
Table 6
Variables associated with hospital discharge

In outcome analysis, we found significantly higher rates of ROSC and survival at 24 hours in the vasopressin/epinephrine group (p < 0.05) (Table (Table1).1). There was no difference in survival to hospital discharge between groups (p = 0.19), but when analyzing the subgroup of patients in asystole, we found a significantly higher hospital discharge rate in patients treated with vasopressin (epinephrine subgroup 17/183 [9.3%] versus vasopressin/epinephrine subgroup 10/44 [22.7%]; p = 0.04; Fisher exact test). In the epinephrine group, significantly higher doses of additional epinephrine were needed, CPR lasted longer, and significantly more patients needed additional atropine, bicarbonate, and inotropic agents than in the vasopressin/epinephrine group (p < 0.05).

Out of all cases of cardiac arrest, 90 patients in the epinephrine group and 36 in the vasopressin/epinephrine group were discharged alive from the hospital. Forty-seven discharged patients in the epinephrine group were with CPC-1 or CPC-2 (52% of survivors), 37 patients with CPC-3 or CPC-4 (41%), and 6 patients with CPC-5 (7%). In the vasopressin/epinephrine group, 26 discharged patients were with CPC-1 or CPC-2 (72%), 8 patients with CPC-3 or CPC-4 (22%), and 2 patients with CPC-5 (6%). Neurological outcome of discharged patients was better (CPC-1 or CPC-2) in the vasopressin/epinephrine group (p = 0.04).

Discussion

In previous studies, the relationship between petCO2 and prognosis was established in prehospital CPR [11-13]. In this study, however, the main focus was on the relationship between petCO2 and MAP and subsequent outcomes. The relevant hemodynamic parameters of resuscitated patients treated with epinephrine only and patients treated with vasopressin (only or in combination with epinephrine) were compared along with their prognostic value in CPR outcome.

The results of this study are similar to those of the studies of Wenzel and colleagues [4] and Guyette and colleagues [5] and show higher rates of ROSC and survival at 24 hours in the group of patients treated with vasopressin. In addition, this study shows that the patients who had asystole as the initial arrest rhythm and who were treated with vasopressin have a higher hospital discharge rate. The average and final petCO2 values in vasopressin-treated patients with ROSC were significantly higher. The initial and the final MAP values were significantly higher in the vasopressin group as well. These results suggest that vasopressin could be more potent than epinephrine in increasing the cardiac output.

Using an animal model, Isserles and Breen [16] established a linear relationship between changes in petCO2 and cardiac output. The authors claim that, during a decreased cardiac output, reduced carbon dioxide delivery to the lung decreases alveolar carbon dioxide pressure and thus causes part of the decrease in petCO2. The remaining reduction in petCO2 results from the increase in alveolar dead space due to the lower pulmonary perfusion pressure (dilution of carbon dioxide from perfused alveolar spaces). Gazmuri and colleagues [17,18] confirmed that both petCO2 and PaCO2 (arterial partial pressure of carbon dioxide) correspond with the pulmonary blood flow and therefore with cardiac output generated by precordial compressions during CPR.

In an animal study, Yannopoulos and colleagues [19] demonstrated a linear correlation between MAP, cerebral perfusion pressure and CPP, and petCO2. A strong correlation between MAP and neurological outcome was observed in a few other studies [20-22]. In a study using a pig model of ventricular fibrillation cardiac arrest, Lindner and colleagues [23] concluded that administration of vasopressin led to a significantly higher CPP, myocardial blood flow, and total cerebral flow during CPR. In a study conducted by Morris and colleagues [24] using a human model of prolonged cardiac arrest, 40% of the patients receiving vasopressin had a significant increase in CPP. Our study shows that higher values of petCO2 and MAP in patients treated with vasopressin are consistent with the better outcomes in the vasopressin group. In a multivariate analysis, we determined that the chances for survival are improved in patients with a higher MAP on admission to the hospital (for every 1.33-kPa increase in MAP, the chances for survival were 1.4 times better). We also determined that the chances for ROSC, survival at 24 hours, and hospital discharge are associated with the year in which CPR was administered (Tables (Tables44 to to6).6). Various factors may cause differences between the two observed time periods. These include implementation of new CPR guidelines, renewal of dispatch protocols, application of vasopressin as first therapy, and improved phone communication.

In our study, we had significantly more patients with CPC-1 and CPC-2 in the vasopressin group than in the epinephrine group. In the postresuscitation period, MAP is usually kept at a normal level (80 to 100 mm Hg) or at least at a level that secures coronary perfusion (that is, 65 mm Hg). Results from the study by Bell and colleagues [25] indicate that, to secure cerebral perfusion and prevent secondary cerebral injury, MAP should be kept at a level higher than commonly accepted. In our study, vasopressin contributed to a higher average final MAP (approximately 105 mm Hg), thus preserving cerebral perfusion in the critical postresuscitation period of absent cerebral autoregulation.

Several investigations have demonstrated that vasopressin could improve hemodynamic variables in advanced vasodilatatory or hemorrhagic shock [26-32]. The study by Friesenecker and colleagues [27] showed that, under normal physiological conditions, vasopressin exerted significantly stronger vasoconstriction on large arterioles than norepinephrine. This observation could explain, in part, why vasopressin can be effective in advanced shock that is unresponsive to increases of catecholamines in the standard shock therapy.

In the epinephrine group, resuscitation efforts lasted longer and a significantly higher quantity of additional epinephrine was needed. Adrenergic stimulation by additional doses of epinephrine is associated with adverse cardiac effects, including postresuscitation myocardial dysfunction and increased myocardial oxygen consumption. That is one of the reasons why significantly larger doses of additional therapy (inotropes, vasopressors, atropine, and bicarbonate) were needed in the epinephrine group in comparison with the vasopressin group.

Increased doses of epinephrine have a direct impact on lowering the petCO2 value [33]. Tang and colleagues [34] in an experimental model and Cantineau and colleagues [35] in a prospective human study established that epinephrine induces pulmonary ventilation/perfusion defects as a result of redistribution of pulmonary blood flow. Other studies show that high doses of epinephrine significantly decrease cardiac output and petCO2 but enhance myocardial perfusion pressure and myocardial blood flow [36,37]. Lindberg and colleagues [38] confirmed that an injection of epinephrine during chest compressions decreased petCO2 and pulmonary blood flow and increased CPP (which then slowly decreased), but the effects on petCO2 and pulmonary blood flow were prolonged. Therefore, epinephrine initially increases CPP and the chances of ROSC, but decreases petCO2 value induced by critical deterioration in cardiac output and thereby diminishes oxygen delivery.

Tang and colleagues [39] confirmed that the beta-adrenergic action of epinephrine has a detrimental effect on postresuscitation myocardial function because it increases myocardial oxygen consumption and decreases postresuscitation survival. In the study by Pan and colleagues [40], CPP was increased after vasopressin application and a significant positive correlation between petCO2 and CPP was observed, suggesting that vasopressin has very little effect on pulmonary circulation and ventilation/perfusion mismatch.

Unlike vasopressin, epinephrine during CPR can, to some extent, reduce petCO2 values because of its impact on the pulmonary circulation. Nevertheless, the values of petCO2, together with MAP, reliably reflect changes in cardiac output.

Conclusion

PetCO2 and MAP values are prognostic factors for the outcome of OHCA. During a cardiac arrest, petCO2 can be considered an indirect parameter for the evaluation of cardiac output in prehospital monitoring together with MAP, when spontaneous circulation is restored. Patients treated with vasopressin alone or followed by epinephrine during CPR have higher average and final petCO2 values as well as higher initial and final MAP values on admission to the hospital than patients treated with epinephrine only. The combination of vasopressor therapy (vasopressin followed by epinephrine) in CPR improves ROSC as well as short-term survival and neurological outcome. In the subgroup of patients with asystole as the initial rhythm, it improves the hospital discharge rate. Our findings suggest that the current guidelines for resuscitation established by the European Resuscitation Council, in which vasopressin is not considered even as a secondary alternative to epinephrine, should be revised.

Key messages

• During CPR, higher petCO2 and MAP values were observed when vasopressin was used.

• PetCO2 and MAP are strong prognostic factors for the outcome of cardiac arrest.

• Compared to epinephrine, vasopressin in CPR improves ROSC as well as short-term survival and neurological outcome.

Abbreviations

ALS = advanced life support; CPC = cerebral performance category; CPP = coronary perfusion pressure; CPR = cardiopulmonary resuscitation; MAP = mean arterial blood pressure; OHCA = out-of-hospital cardiac arrest; petCO2 = end-tidal carbon dioxide tension; ROSC = restoration of spontaneous circulation.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SM participated in conceiving and designing the study and drafted the manuscript. AJ participated in collecting data and helped to draft the manuscript. SG performed the statistical analysis and made critical revisions of the study. All authors have read and approved the final manuscript.

Notes

See related commentary by Morley, http://ccforum.com/content/11/3/130

References

  • Wenzel V, Lindner KH. Vasopressin combined with epinephrine during cardiac resuscitation: a solution for the future? Crit Care. 2006;10:125. doi: 10.1186/cc4846. [PMC free article] [PubMed] [Cross Ref]
  • Ditchey RV, Lindenfeld J. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation. 1988;78:382–389. [PubMed]
  • Paradis NA, Wenzel V, Southall J. Pressor drugs in the treatment of cardiac arrest. Cardiol Clin. 2002;20:61–78. doi: 10.1016/S0733-8651(03)00065-1. [PubMed] [Cross Ref]
  • Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004;350:105–113. doi: 10.1056/NEJMoa025431. [PubMed] [Cross Ref]
  • Guyette FX, Guimond GE, Hostler D, Callaway CW. Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation. 2004;63:277–282. doi: 10.1016/j.resuscitation.2004.05.007. [PubMed] [Cross Ref]
  • Grmec S, Mally S. Vasopressin improves outcome in out-of-hospital cardiopulmonary resuscitation of ventricular fibrillation and pulseless ventricular tachycardia: a observational cohort study. Crit Care. 2006;10:R13. doi: 10.1186/cc3967. [PMC free article] [PubMed] [Cross Ref]
  • Krismer AC, Wenzel V, Stadlbauer KH, Mayr VD, Lienhart HG, Arntz HR, Lindner KH. Vasopressin during cardiopulmonary resuscitation: a progress report. Crit Care Med. 2004;32:S432–435. doi: 10.1097/01.CCM.0000134267.91520.C0. [PubMed] [Cross Ref]
  • Lewis LM, Stothert J, Standeven J, Chandel B, Kurtz M, Fortney J. Correlation of end-tidal CO2 to cerebral perfusion during CPR. Ann Emerg Med. 1992;21:1131–1134. doi: 10.1016/S0196-0644(05)80658-4. [PubMed] [Cross Ref]
  • Idris AH, Staples ED, O'Brien DJ, Melker RJ, Rush WJ, Del Duca KD, Falk JL. End-tidal carbon dioxide during extremely low cardiac output. Ann Emerg Med. 1994;23:568–572. doi: 10.1016/S0196-0644(94)70080-X. [PubMed] [Cross Ref]
  • Shibutani K, Muraoka M, Shirasaki S, Kubal K, Sanchala VT, Gupte P. Do changes in end-tidal PCO2 quantitatively reflect changes in cardiac output? Anesth Analg. 1994;79:829–833. doi: 10.1213/00000539-199411000-00002. [PubMed] [Cross Ref]
  • Grmec S, Lah K, Tusek-Bunc K. Difference in end-tidal CO2 between asphyxia cardiac arrest and ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest in the prehospital setting. Crit Care. 2003;7:R139–144. doi: 10.1186/cc2369. [PMC free article] [PubMed] [Cross Ref]
  • Grmec S, Kupnik D. Does the Mainz Emergency Evaluation Scoring (MEES) in combination with capnometry (MEESc) help in the prognosis of outcome from cardiopulmonary resuscitation in a prehospital setting? Resuscitation. 2003;58:89–96. doi: 10.1016/S0300-9572(03)00116-3. [PubMed] [Cross Ref]
  • Salen P, O'Connor R, Sierzenski P, Passarello B, Pancu D, Melanson S, Arcona S, Reed J, Heller M. Can cardiac sonography and capnography be used independently and in combination to predict resuscitation outcomes? Acad Emerg Med. 2001;8:610–615. [PubMed]
  • Müllner M, Sterz F, Binder M, Hellwagner K, Meron G, Herkner H, Laggner AN. Arterial blood pressure after human cardiac arrest and neurological recovery. Stroke. 1996;27:59–62. [PubMed]
  • Sundgreen C, Larsen FS, Herzog TM, Knudsen GM, Boesgaard S, Aldershvile J. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke. 2001;32:128–132. [PubMed]
  • Isserles SA, Breen PH. Can changes in end-tidal PCO2 measure changes in cardiac output? Anesth Analg. 1991;73:808–814. doi: 10.1213/00000539-199112000-00023. [PubMed] [Cross Ref]
  • Gazmuri RJ, von Planta M, Weil MH, Rackow EC. Arterial PCO2 as an indicator of systemic perfusion during cardiopulmonary resuscitation. Crit Care Med. 1989;17:237–240. doi: 10.1097/00003246-198903000-00007. [PubMed] [Cross Ref]
  • Gazmuri RJ, Weil MH, Bisera J, Rackow EC. End-tidal carbon dioxide tension as a monitor of native blood flow during resuscitation by extracorporeal circulation. J Thorac Cardiovasc Surg. 1991;101:984–988. [PubMed]
  • Yannopoulos D, Aufderheide TP, McKnite S, Kotsifas K, Charris R, Nadkarni V, Lurie KG. Hemodynamic and respiratory effects of negative tracheal pressure during CPR in pigs. Resuscitation. 2006;69:487–494. doi: 10.1016/j.resuscitation.2005.11.005. [PubMed] [Cross Ref]
  • Ornato JP, Levine RL, Young DS, Racht EM, Garnett AR, Gonzalez ER. The effect of applied chest compression force on systemic arterial pressure and end-tidal carbon dioxide concentration during CPR in human beings. Ann Emerg Med. 1989;18:732–737. doi: 10.1016/S0196-0644(89)80005-8. [PubMed] [Cross Ref]
  • Li G, Tang N, DiScala C, Meisel Z, Levick N, Kelen GD. Cardiopulmonary resuscitation in pediatric trauma patients: survival and functional outcome. J Trauma. 1999;47:1–7. [PubMed]
  • Engdahl J, Abrahamsson P, Bang A, Lindqvist J, Karlsson T, Herlitz J. Is hospital care of major importance for outcome after out-of-hospital cardiac arrest? Experience acquired from patients with out-of-hospital cardiac arrest resuscitated by the same Emergency Medical Service and admitted to one of two hospitals over a 16-year period in the municipality of Göteborg. Resuscitation. 2000;43:201–211. doi: 10.1016/S0300-9572(99)00154-9. [PubMed] [Cross Ref]
  • Lindner KH, Prengel AW, Pfenninger EG, Lindner IM, Strohmenger HU, Georgieff M, Lurie KG. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation. 1995;91:215–221. [PubMed]
  • Morris DC, Dereczyk BE, Grzybowski M, Martin GB, Rivers EP, Wortsman J, Amico JA. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med. 1997;4:878–883. [PubMed]
  • Bell DD, Brindley PG, Forrest D, Al Muslim O, Zygun D. Management following resuscitation from cardiac arrest: recommendations from the 2003 Rocky Mountain Critical Care Conference. Can J Anaesth. 2005;52:309–322. [PubMed]
  • Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33:2659–2666. doi: 10.1097/01.CCM.0000186749.34028.40. [PubMed] [Cross Ref]
  • Friesenecker BE, Tsai AG, Martini J, Ulmer H, Wenzel V, Hasibeder WR, Intaglietta M, Dünser MW. Arteriolar vasoconstrictive response: comparing the effects of arginine vasopressin and norepinephrine. Crit Care. 2006;10:R75. doi: 10.1186/cc4922. [PMC free article] [PubMed] [Cross Ref]
  • Raedler C, Voelckel WG, Wenzel V, Krismer AC, Schmittinger CA, Herff H, Mayr VD, Stadlbauer KH, Lindner KH, Königsrainer A. Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg. 2004;98:1759–1766. doi: 10.1213/01.ANE.0000117150.29361.5A. [PubMed] [Cross Ref]
  • Krismer AC, Wenzel V, Voelckel WG, Innerhofer P, Stadlbauer KH, Haas T, Pavlic M, Sparr HJ, Lindner KH, Königsrainer A. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist. 2005;54:220–224. doi: 10.1007/s00101-004-0793-y. [PubMed] [Cross Ref]
  • Tsuneyoshi I, Onomoto M, Yonetani A, Kanmura Y. Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth. 2005;19:170–173. doi: 10.1007/s00540-004-0299-4. [PubMed] [Cross Ref]
  • Grmec S, Cander D, Strnad M, Vidovic D. Does vasopressin improve the outcome in traumatic out-of-hospital cardiac arrest from pulseless electrical activity (TOOHCA-PEA)? Crit Care Med. 2005;33:A127. doi: 10.1097/00003246-200512002-00449. (abstract) [Cross Ref]
  • Krismer AC, Dünser MW, Lindner KH, Stadlbauer KH, Mayr VD, Lienhart HG, Arntz RH, Wenzel V. Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature. Am J Cardiovasc Drugs. 2006;6:51–68. doi: 10.2165/00129784-200606010-00005. [PubMed] [Cross Ref]
  • Martin GB, Gentile NT, Paradis NA, Moeggenberg J, Appleton TJ, Nowak RM. Effect of epinephrine on end-tidal carbon dioxide monitoring during CPR. Ann Emerg Med. 1990;19:396–398. doi: 10.1016/S0196-0644(05)82345-5. [PubMed] [Cross Ref]
  • Tang W, Weil MH, Gazmuri RJ, Sun S, Duggal C, Bisera J. Pulmonary ventilation/perfusion defects induced by epinephrine during cardiopulmonary resuscitation. Circulation. 1991;84:2101–2107. [PubMed]
  • Cantineau JP, Merckx P, Lambert Y, Sorkine M, Bertrand C, Duvaldestin P. Effect of epinephrine on end-tidal carbon dioxide pressure during prehospital cardiopulmonary resuscitation. Am J Emerg Med. 1994;12:267–270. doi: 10.1016/0735-6757(94)90136-8. [PubMed] [Cross Ref]
  • Rivers EP, Wortsman J, Rady MY, Blake HC, McGeorge FT, Buderer NM. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest. 1994;106:1499–1507. [PubMed]
  • Chase PB, Kern KB, Sanders AB, Otto CW, Ewy GA. Effects of graded doses of epinephrine on both noninvasive and invasive measures of myocardial perfusion and blood flow during cardiopulmonary resuscitation. Crit Care Med. 1993;21:413–419. doi: 10.1097/00003246-199303000-00020. [PubMed] [Cross Ref]
  • Lindberg L, Liao Q, Steen S. The effects of epinephrine/norepinephrine on end-tidal carbon dioxide concentration, coronary perfusion pressure and pulmonary arterial blood flow during cardiopulmonary resuscitation. Resuscitation. 2000;43:129–140. doi: 10.1016/S0300-9572(99)00129-X. [PubMed] [Cross Ref]
  • Tang W, Weil MH, Sun S, Noc M, Yang L, Gazmuri RJ. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation. 1995;92:3089–3093. [PubMed]
  • Pan T, Zhou S, Studer W, von Planta M, Scheidegger D. Effect of different drugs on end-tidal carbon dioxide during rodent CPR. J Tongji Med Univ. 1997;17:244–246. [PubMed]

Articles from Critical Care are provided here courtesy of BioMed Central
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...